Search Results
May 20, 2026, 08:00 ET Pinnaql Acquires Pharma Resource Group, Expanding Engineering, Validation, Tech Transfer, and Manufacturing Support for Life Sciences Clients
commitment as a full-lifecycle partner for its clients.Together, the combined organizations are equipped to support pharmaceutical, biotechnology, and CDMO clients through every phase of product development and commercialization — delivering technically rigorous, inspection-ready solutions aligned with
More news about: Pinnaql
May 20, 2026, 07:00 ET Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
other things, statements regarding the Company's CDMO growth strategy, expansion of operational capabilities, integration of the Yavne facility into Scinai Biopharma Services' CDMO platform, management transition activities, expansion of the Company's CDMO operations, execution of commercial collaboration
More news about: Scinai Immunotherapeutics Ltd.
May 19, 2026, 16:38 ET VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that provides biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to
More news about: Valion Bio, Inc.
May 19, 2026, 16:13 ET Avid Bioservices nomme Maria Ebro Andreasen au poste de Chief People Officer pour soutenir la croissance continue et la stratégie des talents
TUSTIN, Californie, 19 mai 2026 /PRNewswire/ -- Avid Bioservices, l'un des principaux CDMO de produits biologiques, annonce aujourd'hui la nomination de Maria Ebro Andreasen au poste de Chief People Officer.
More news about: Avid Bioservices
May 19, 2026, 15:59 ET Avid Bioservices ernennt Maria Ebro Andreasen zur Personalchefin, um das weitere Wachstum und die Talentstrategie voranzutreiben
TUSTIN, Kalifornien, 19. Mai 2026 /PRNewswire/ -- Avid Bioservices, ein führender CDMO-Anbieter für Biologika, gab heute die Ernennung von Maria Ebro Andreasen zur Personalvorstand bekannt.
More news about: Avid Bioservices
May 19, 2026, 06:00 ET FAMAR Group announces contract manufacturing agreement with GE HealthCare
May 19, 2026 /PRNewswire/ -- FAMAR Group, a leading European pharmaceutical Contract Development and Manufacturing Organization (CDMO), has signed a contract manufacturing agreement with GE HealthCare to fill and finish vials of GE HealthCare's iodine-based contrast media, at
More news about: FAMAR Group
May 19, 2026, 02:12 ET Avid Bioservices nombra a Maria Ebro Andreasen como directora de Recursos Humanos
TUSTIN, Calif., 19 de mayo de 2026 /PRNewswire/ -- Avid Bioservices, una importante CDMO de productos biológicos, anunció hoy el nombramiento de Maria Ebro Andreasen como directora de Recursos Humanos.
More news about: Avid Bioservices
May 18, 2026, 12:42 ET Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy
TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading biologics CDMO, today announced the appointment of Maria Ebro Andreasen as Chief People Officer.
More news about: Avid Bioservices
May 18, 2026, 12:31 ET Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy
TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading biologics CDMO, today announced the appointment of Maria Ebro Andreasen as Chief People Officer.
More news about: Avid Bioservices
May 18, 2026, 09:00 ET Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary
More news about: Piramal Pharma Solutions
May 18, 2026, 09:00 ET Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary
More news about: Piramal Pharma Solutions
May 18, 2026, 09:00 ET Piramal Pharma Solutions kündigt Partnerschaft mit Botanix zur Unterstützung der Wirkstoffentwicklung an
18. Mai 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), ein weltweit führendes Auftragsentwicklungs- und -herstellungsunternehmen (CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), hat mit Botanix SB Inc., einer Tochtergesellschaft von Botanix Pharmaceuticals
More news about: Piramal Pharma Solutions
May 18, 2026, 09:00 ET Piramal Pharma Solutions annuncia una collaborazione con Botanix per promuovere lo sviluppo dei principi attivi
(PPS), organizzazione leader a livello mondiale nello sviluppo e nella produzione a contratto (Contract Development and Manufacturing Organization, CDMO) e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha siglato un accordo di produzione e fornitura con Botanix SB Inc., una controllata
More news about: Piramal Pharma Solutions
May 18, 2026, 09:00 ET Piramal Pharma Solutions anuncia una alianza con Botanix para el desarrollo de sustancias farmacéuticas
18 de mayo de 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), una organización líder mundial de desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha firmado un acuerdo de fabricación y suministro con Botanix SB Inc., una filial de
More news about: Piramal Pharma Solutions
May 18, 2026, 09:00 ET Piramal Pharma Solutions annonce un partenariat avec Botanix pour soutenir le développement de substances médicamenteuses
18 mai 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), une organisation de développement et de fabrication sous contrat (CDMO) de premier plan au niveau mondial et faisant partie de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE : 543635), vient de signer un accord de fabrication
More news about: Piramal Pharma Solutions
May 17, 2026, 20:00 ET LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
relationship and reinforces LOTTE Biologics' commitment to supporting clients from clinical development through commercialization.As a pure-play CDMO, LOTTE Biologics delivers integrated services across development and manufacturing, backed by its dual-site strategy spanning the Syracuse Bio Campus
More news about: LOTTE Biologics
May 17, 2026, 20:00 ET LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
relationship and reinforces LOTTE Biologics' commitment to supporting clients from clinical development through commercialization.As a pure-play CDMO, LOTTE Biologics delivers integrated services across development and manufacturing, backed by its dual-site strategy spanning the Syracuse Bio Campus
More news about: LOTTE Biologics
May 15, 2026, 08:05 ET Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Planck Society and from PinCell S.r.l.Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.For more information, please visit:
More news about: Scinai Immunotherapeutics Ltd.
May 14, 2026, 16:31 ET Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
an advanced diagnostics service offering that we believe will benefit the biomanufacturing of programs both our internal pipeline and our third-party CDMO clients."The San Antonio installation, targeted for commissioning in July 2026, is expected to anchor Velocity Bioworks' advanced diagnostics
More news about: Valion Bio, Inc.
May 14, 2026, 16:05 ET VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
company's wholly owned contract development and manufacturing organization (CDMO) subsidiary acquired in December 2025, with operational workstreams advancing across both internal pipeline manufacturing support and third-party CDMO business development. Reinforced regulatory pathway for
More news about: Valion Bio, Inc.
May 14, 2026, 08:30 ET Improve Fill-Finish Yield for Today's High-Value Drug Products, Upcoming Webinar Hosted by Xtalks
aseptic fill-finish and outlines practical ways to preserve more drug product.Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible for clients with rare or expensive APIs? In this webinar, the featured speakers
More news about: Xtalks
May 14, 2026, 08:08 ET Piramal Pharma Solutions svela la suite di linker-payload all'avanguardia presso il suo stabilimento di Riverview, Michigan
Solutions, un'organizzazione leader a livello mondiale nello sviluppo e nella produzione a contratto (Contract Development and Manufacturing Organization, CDMO) e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPS"), ha presentato ufficialmente una nuova suite all'avanguardia per lo sviluppo e
More news about: Piramal Pharma Solutions
May 14, 2026, 07:45 ET Piramal Pharma Solutions dévoile une suite payload-linker ultramoderne dans ses installations de Riverview, Michigan
14 mai 2026 /PRNewswire/ -- Piramal Pharma Solutions, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, qui fait partie de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) (« PPS »), a officiellement dévoilé une nouvelle unité de développement
More news about: Piramal Pharma Solutions
May 13, 2026, 23:13 ET Piramal Pharma Solutions presenta su suite de última generación para conectores de carga útil
14 de mayo de 2026 /PRNewswire/ -- Piramal Pharma Solutions, una organización líder mundial de desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPS"), ha presentado oficialmente una nueva y vanguardista planta de desarrollo y fabricación
More news about: Piramal Pharma Solutions
May 13, 2026, 23:08 ET Piramal Pharma Solutions enthüllt hochmoderne Payload-Linker-Suite in seinem Werk in Riverview, Michigan
Piramal Pharma Solutions, ein weltweit führendes Auftragsentwicklungs- und Herstellungsunternehmen (Contract Development and Manufacturing Organization, CDMO) und Teil der Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) („PPS"), hat in seiner Wirkstoffproduktionsstätte in Riverview, Michigan, offiziell
More news about: Piramal Pharma Solutions